EA202000298A1 - ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT - Google Patents

ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT

Info

Publication number
EA202000298A1
EA202000298A1 EA202000298A EA202000298A EA202000298A1 EA 202000298 A1 EA202000298 A1 EA 202000298A1 EA 202000298 A EA202000298 A EA 202000298A EA 202000298 A EA202000298 A EA 202000298A EA 202000298 A1 EA202000298 A1 EA 202000298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cov
sars
covid
treatment
agent
Prior art date
Application number
EA202000298A
Other languages
Russian (ru)
Inventor
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Original Assignee
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович ИВАЩЕНКО, Александр Васильевич ИВАЩЕНКО, Николай Филиппович САВЧУК, Алёна Александровна Иващенко, Владимир Григорьевич ЛОГИНОВ, Михаил ТОПР filed Critical Андрей Александрович ИВАЩЕНКО
Publication of EA202000298A1 publication Critical patent/EA202000298A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к новому противокоронавирусному средству для комбинированной терапии COVID-19 (SARS-CoV-2). Средство включает в терапевтически эффективном количестве и соотношении апротинин (АПР) или лекарственный препарат на его основе и ингибитор репликации SARS-CoV-2. Лекарственный препарат на основе апротинина предпочтительно выбирается из группы, представляющей собой Апротекс, Веро-Наркап, Ингитрил, Контрикал, Контрисел, Трасилол, Ингипрол, Апротимбин, Гордокс, Контривен, Трасколан или Аэрус. В качестве ингибитора репликации SARS-CoV-2 может быть использован фавопиравир (ФВП) или Ремдесевир (РМД) или лекарственный препарат на их основе. Лекарственный препарат на основе фавипиравира предпочтительно выбирается из группы, представляющей собой Авиган, Фавилавир, Авифавир, Коронавир или Фабифлю. Изобретение также относится к комбинированному способу лечения COVID-19 (SARS-CoV-2) введением пациенту с COVID-19 указанного противокоронавирусного средства. Применение нового противокоронавирусного средства приводит к новому и синергетическому эффекту при лечении COVID-19 (SARS-CoV-2), позволяет значительно сократить сроки лечения и уменьшить риск появления нежелательных побочных явлений.The invention relates to a new anti-coronavirus agent for combination therapy of COVID-19 (SARS-CoV-2). The agent includes a therapeutically effective amount and ratio of aprotinin (APR) or a drug based on it and an inhibitor of SARS-CoV-2 replication. The aprotinin-based drug is preferably selected from the group consisting of Aprotex, Vero-Narcap, Ingitril, Contrical, Contrisel, Trasilol, Ingiprol, Aprotimbin, Gordox, Contriven, Traskolan or Aerus. Favopiravir (FVP) or Remdesavir (RMD) or a drug based on them can be used as an inhibitor of SARS-CoV-2 replication. The favipiravir drug is preferably selected from the group consisting of Avigan, Favilavir, Avifavir, Coronavir or Fabiflu. The invention also relates to a combined method for the treatment of COVID-19 (SARS-CoV-2) by administering said anti-coronavirus agent to a patient with COVID-19. The use of a new anti-coronavirus agent leads to a new and synergistic effect in the treatment of COVID-19 (SARS-CoV-2), can significantly reduce the treatment time and reduce the risk of unwanted side effects.

EA202000298A 2020-08-21 2020-10-22 ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT EA202000298A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020127971A RU2745986C1 (en) 2020-08-21 2020-08-21 Covid-19 (sars-cov-2) combination therapy and treatment method

Publications (1)

Publication Number Publication Date
EA202000298A1 true EA202000298A1 (en) 2022-02-28

Family

ID=75353441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202000298A EA202000298A1 (en) 2020-08-21 2020-10-22 ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT

Country Status (2)

Country Link
EA (1) EA202000298A1 (en)
RU (1) RU2745986C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177366A1 (en) * 2022-03-18 2023-09-21 Pulmocures Ilac Egitim Danismanlik A.S. Use of active ingredient used against viral diseases with pressurized metered dose inhaler in the treatment of covid-19 and other viral lung diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711080C2 (en) * 2015-06-15 2020-01-15 Олег Петрович Жирнов Combined aerosol composition based on protease inhibitors and preparation thereof

Also Published As

Publication number Publication date
RU2745986C1 (en) 2021-04-05

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
RU2018110647A (en) Aryl, heteroaryl and heterocyclic compounds for the treatment of diseases
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
CA2474479A1 (en) Composition for inhalation
EA202092343A1 (en) TREATMENT OF PURULENT HYDRADENITIS WITH THE USE OF JAK INHIBITORS
NZ600000A (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2021011230A (en) Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases.
MX2022012923A (en) Inhibitors of trpc6 for treating respiratory conditions.
MX2022016406A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib.
ATE414522T1 (en) METHOD FOR TREATING ACUTE AND EXCESSIVE EXERCISE STRAINS AND SPARES USING HYALURONIC ACID
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
MX2021004207A (en) Use of reboxetine to treat narcolepsy.
MX2020001254A (en) Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor.
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
EA202190798A1 (en) ROTAMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2-DITHIOL-3-THIONES
AR127966A1 (en) TOPICAL FORMULATIONS OF PI3K-DELTA INHIBITORS
EA202000299A1 (en) ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2)
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
ATE487480T1 (en) PERHEXILINE FOR THE TREATMENT OF CHRONIC HEART FAILURE
CL2021003303A1 (en) Treatment for synucleinopathies.
MX2023013514A (en) Methods of treating interstitial cystitis/bladder pain syndrome.
MX2023004516A (en) Use of pridopidine and analogs for the treatment of anxiety and depression.
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury